• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    4/18/24 12:31:41 PM ET
    $ALRN
    $APM
    $BNTC
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALRN alert in real time by email

    Gainers

    • Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. The market value of their outstanding shares is at $4.0 million.
    • Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 53.88% to $6.54. The company's market cap stands at $111.0 million. As per the press release, Q4 earnings came out 3 days ago.
    • 23andMe Holding (NASDAQ:ME) stock moved upwards by 45.48% to $0.52. The company's market cap stands at $250.2 million.
    • SINTX Techs (NASDAQ:SINT) stock moved upwards by 40.75% to $0.05. The company's market cap stands at $6.4 million.
    • iSpecimen (NASDAQ:ISPC) shares moved upwards by 33.19% to $0.28. The company's market cap stands at $2.5 million.
    • Benitec Biopharma (NASDAQ:BNTC) shares moved upwards by 25.62% to $6.03. The market value of their outstanding shares is at $15.6 million.

    Losers

    • SeaStar Medical Holding (NASDAQ:ICU) stock decreased by 27.0% to $0.51 during Thursday's regular session. The company's market cap stands at $38.4 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Aptorum Gr (NASDAQ:APM) stock declined by 26.35% to $5.34. The company's market cap stands at $29.2 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock fell 25.12% to $3.13. The market value of their outstanding shares is at $29.9 million.
    • Genetic Technologies (NASDAQ:GENE) stock fell 23.74% to $2.41. The market value of their outstanding shares is at $9.2 million.
    • Ontrak (NASDAQ:OTRK) stock fell 20.39% to $0.29. The market value of their outstanding shares is at $13.8 million. As per the press release, Q4 earnings came out 2 days ago.
    • INVO Bioscience (NASDAQ:INVO) stock decreased by 20.34% to $1.45. The market value of their outstanding shares is at $3.9 million. The company's, Q4 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALRN
    $APM
    $BNTC
    $BPTH

    CompanyDatePrice TargetRatingAnalyst
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    7/7/2025Buy
    TD Cowen
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    Benitec Biopharma Inc.
    $BNTC
    12/16/2024$28.00Buy
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    12/13/2024$30.00Outperform
    Robert W. Baird
    Benitec Biopharma Inc.
    $BNTC
    10/16/2024$35.00Outperform
    Oppenheimer
    Benitec Biopharma Inc.
    $BNTC
    9/12/2024$17.00Buy
    Guggenheim
    Benitec Biopharma Inc.
    $BNTC
    7/22/2024$13.00Outperform
    Leerink Partners
    More analyst ratings

    $ALRN
    $APM
    $BNTC
    $BPTH
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Other Events

    8-K - iSpecimen Inc. (0001558569) (Filer)

    3/13/26 5:00:30 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/11/26 4:00:01 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/6/26 4:30:58 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALRN
    $APM
    $BNTC
    $BPTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ALRN
    $APM
    $BNTC
    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

    Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, today announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry int

    3/19/26 7:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ALRN
    $APM
    $BNTC
    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ALRN
    $APM
    $BNTC
    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by SiNtx Technologies Inc.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/18/26 9:02:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on NRx Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/8/25 8:58:39 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Benitec Biopharma

    TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

    7/7/25 8:17:08 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

    BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

    4/2/25 8:51:11 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALRN
    $APM
    $BNTC
    $BPTH
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ALRN
    $APM
    $BNTC
    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALRN
    $APM
    $BNTC
    $BPTH
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

    WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00am ET. The call will provide a corporate update, including recent clinical, regulatory, and operational developments. A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865. About NRx P

    12/2/25 7:30:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care